-transparent.png){kind=logo}
Recent efforts have been made to develop a chemical oviductal occluding agent. Intrauterine quinacrine has been used in certain areas of the world with moderate success in effected tubal closure. This report presents the pharmacokinetics of a quinacrine solution (30 mg) as administered to cynomolgus monkeys via the intrauterine route, compared with intravascular injection. The data show rapid transfer of the drug from the uterine to the vascular compartment and uptake by almost all tissues examined. Although plasma concentrations disappear within 24 hours, levels can be detected in most tissues for at least 1 week following intrauterine injection. After 28 days, however, tissue levels of the drug are absent or near the limit of detection.
N H Dubin, and
D A Blake, and
M C DiBlasi, and
T H Parmley, and
T M King
June 1984,
Contraception,
N H Dubin, and
D A Blake, and
M C DiBlasi, and
T H Parmley, and
T M King
January 1982,
Beitrage zur gerichtlichen Medizin,
N H Dubin, and
D A Blake, and
M C DiBlasi, and
T H Parmley, and
T M King
June 1988,
Klinische Monatsblatter fur Augenheilkunde,
N H Dubin, and
D A Blake, and
M C DiBlasi, and
T H Parmley, and
T M King
April 1998,
Biopharmaceutics & drug disposition,
N H Dubin, and
D A Blake, and
M C DiBlasi, and
T H Parmley, and
T M King
October 1955,
Cancer research,
N H Dubin, and
D A Blake, and
M C DiBlasi, and
T H Parmley, and
T M King
December 2022,
Reproductive toxicology (Elmsford, N.Y.),
N H Dubin, and
D A Blake, and
M C DiBlasi, and
T H Parmley, and
T M King
January 1986,
Acta radiologica: diagnosis,
N H Dubin, and
D A Blake, and
M C DiBlasi, and
T H Parmley, and
T M King
January 2010,
International journal of immunopathology and pharmacology,
N H Dubin, and
D A Blake, and
M C DiBlasi, and
T H Parmley, and
T M King
December 2009,
Biological & pharmaceutical bulletin,
N H Dubin, and
D A Blake, and
M C DiBlasi, and
T H Parmley, and
T M King
January 1961,
Texas reports on biology and medicine,
